Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study

Runcheng He, Yuwen Zhao, Yan He, Yangjie Zhou, Jinxia Yang, Xiaoting Zhou, Liping Zhu, Xun Zhou, Zhenhua Liu, Qian Xu, Qiying Sun, Jieqiong Tan, Xinxiang Yan, Beisha Tang, Jifeng GuoFrontiers in Neuroscience 2020 · DOI

Abstract

Our prospective study demonstrated that hyposmic Parkinson’s disease (PD) patients showed a relatively worse clinical course compared with normosmic patients. Olfactory dysfunction is a useful predictor of disease progression, particularly regarding motor deterioration and cognitive decline.

Introduction

Parkinson’s Disease (PD) is characterized by significant clinical heterogeneity, with disease progression rates varying widely among patients. Identifying reliable biomarkers to predict this trajectory is critical for personalized clinical management. While olfactory dysfunction (hyposmia) is a well-recognized prodromal symptom of PD, its role as a longitudinal predictor of disease severity has remained under-explored. Most existing research has relied on cross-sectional data, providing only a snapshot of the relationship between smell loss and PD symptoms. This study addresses this gap by investigating whether the severity of hyposmia at baseline can predict the rate of motor and cognitive decline over a two-year period.

Methods

This prospective study followed a cohort of PD patients recruited from the Parkinson’s Disease and Movement Disorders Multicenter Database and Collaborative Network in China (PD-MDCNC). The final analysis included 164 patients (105 hyposmic and 59 normosmic) who completed a two-year follow-up.

Flow chart of patients with Parkinson’s disease included in the study.

Olfactory function was assessed using the "Sniffin’ Sticks" test, which evaluates three distinct domains: odor threshold (T), discrimination (D), and identification (I), resulting in a composite TDI score. Clinical progression was monitored annually using the Unified Parkinson’s Disease Rating Scale (UPDRS) for motor symptoms and the Mini-Mental State Examination (MMSE) for cognitive function. Additionally, the Levodopa Equivalent Dose (LED) was tracked to measure medication requirements. Statistical analyses, including linear mixed-effect models, were employed to control for confounding variables such as age, gender, and disease duration.

Results

The study revealed significant differences in the clinical trajectories of hyposmic versus normosmic patients across several key metrics.

Motor Progression and Medication Requirements

While baseline motor scores were similar between groups, hyposmic patients exhibited significantly worse motor symptoms (UPDRS Part III) by the one-year follow-up (p = 0.030). Furthermore, hyposmic patients required substantially higher doses of dopaminergic medication by the second year. The mean LED for the hyposmic group reached 560.21 mg, compared to 465.15 mg for the normosmic group (p = 0.020). Despite these higher doses, hyposmic patients showed less overall motor improvement, suggesting a relative resistance to standard dopamine replacement therapy.

Longitudinal clinical assessments of hyposmic and normosmic PD patients over two years.

Cognitive Decline

Cognitive stability differed markedly between the two groups. Hyposmic patients experienced a significant longitudinal decline in total MMSE scores, dropping from a baseline of 27.31 to 26.99 by year two (p = 0.041). In contrast, normosmic patients remained cognitively stable. This decline was specifically pronounced in the "attention and calculation" domain (p = 0.048).

Phenotypic Associations

Hyposmic patients were more frequently classified with the Postural Instability and Gait Difficulty (PIGD) phenotype, which is typically associated with a more aggressive disease course than the Tremor Dominant (TD) phenotype. Notably, odor identification (the "I" score) emerged as the strongest individual predictor of both motor and cognitive outcomes.

Discussion

The findings support the hypothesis that severe olfactory dysfunction may reflect a higher "pathology load" within the brain, potentially aligning with Braak’s staging model where PD pathology originates in the olfactory bulb before spreading to more critical motor and cognitive centers. The correlation between odor identification and cognitive decline suggests that the central processing of olfactory information is closely linked to broader neurodegenerative processes.

Limitations and Future Directions

While this study provides strong evidence for hyposmia as a prognostic marker, the two-year duration is relatively short for a chronic condition like PD. Longer-term follow-up is necessary to determine if baseline hyposmia predicts the eventual onset of PD dementia or severe gait freezing. Additionally, future research should integrate these clinical findings with neuroimaging data to map the structural brain changes associated with rapid progression in hyposmic patients.

Conclusion

Olfactory testing, particularly odor identification, serves as a powerful and non-invasive tool for predicting disease progression in PD. Patients presenting with significant hyposmia at baseline should be monitored more closely for rapid motor deterioration and cognitive decline.

Summary updated

Abstract

Our prospective study demonstrated that hyposmic PD patients showed a relatively worse clinical course compared with normosmic patients. Olfactory dysfunction is a useful predictor of disease progression.
BibTeX
@inproceedings{he2020olfactory,
  author = {Runcheng He and Yuwen Zhao and Yan He and Yangjie Zhou and Jinxia Yang and Xiaoting Zhou and Liping Zhu and Xun Zhou and Zhenhua Liu and Qian Xu and Qiying Sun and Jieqiong Tan and Xinxiang Yan and Beisha Tang and Jifeng Guo},
  title = {{Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study}},
  booktitle = {Frontiers in Neuroscience},
  year = {2020},
  doi = {10.3389/fnins.2020.569777},
}
Figure